oleanolic acid has been researched along with Diabetes Mellitus, Type 2 in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.64) | 29.6817 |
| 2010's | 55 (90.16) | 24.3611 |
| 2020's | 5 (8.20) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, K; Ha, do T; Ngoc, TM; Nhiem, NX; Thu, NB; Tuan, DT; Yim, N | 1 |
| Ishikawa, M; Kanno, S; Nakazawa, T; Namikoshi, M; Sumilat, DA; Takahashi, O; Takahashi, S; Ukai, K; Yamazaki, H | 1 |
| Gu, J; Min, Z; Wang, R; Wang, S; Yan, Y | 1 |
| Cao, H; Fang, WS; Gao, X; Huan, Y; Niu, S; Shen, Z; Wang, S; Wang, X; Yang, M; Zhou, X | 1 |
| Chen, X; Hu, Z; Kang, L; Liu, B; Liu, Y; Niu, K; Xing, H | 1 |
| Ito, M; Nangaku, M | 1 |
| Alarcón-Aguilar, FJ; Almanza-Pérez, JC; Aquino-Jarquín, G; Estrada-Soto, S; Fortis-Barrera, Á; Giacoman-Martínez, A; Huang, F; Loza-Rodríguez, H | 1 |
| Block, GA; Chertow, GM; Chin, MP; Ferguson, DA; Goldsberry, A; Jadoul, M; Lewis, JH; Meyer, CJ; O'Grady, M; Pergola, PE; Reisman, SA; Wigley, WC | 1 |
| Nezu, M; Suzuki, N; Yamamoto, M | 1 |
| Bhattacharjee, N; Dewanjee, S; Dua, TK; Kalita, J; Khanra, R; Manna, P; Nandy, A; Saha, A | 1 |
| Bakris, GL; Block, GA; Chertow, GM; Chin, MP; Goldsberry, A; Heerspink, HJL; Inker, LA; Meyer, CJ; O'Grady, M; Pergola, PE; Wanner, C; Warnock, DG | 1 |
| Dang, LH; Ha, TKQ; Hoang, MC; Lee, CH; Nguyen, TBT; Oh, WK; Pham, HTT; Tran, VO | 1 |
| Gamede, M; Khathi, A; Mabuza, L; Ngubane, P | 1 |
| Dirmenci, T; Erim, FB; Kalaycıoğlu, Z; Uzaşçı, S | 1 |
| Appel, GB; Block, GA; Chertow, GM; Chin, MP; Coyne, DW; Goldsberry, A; Kalantar-Zadeh, K; Meyer, CJ; Molitch, ME; Pergola, PE; Raskin, P; Rossing, P; Silva, AL; Spinowitz, B; Sprague, SM | 1 |
| Chin, MP; Goldsberry, A; McCullough, PA; Meyer, CJ; O'Grady, M; Pergola, PE; Rizk, DV; Silva, AL; Toto, R; Warnock, DG | 1 |
| Ángel-Lugo, A; Castellano, JM; Cayuela, JA; Gómez-Martín, AM; Guinda, Á; Jiménez-Rodríguez, MC; Lapetra, J; Ortega-Calvo, M; Rada, M; Santos-Lozano, JM; Vilches-Arenas, Á | 1 |
| Block, GA; Chertow, GM; Chin, MP; Goldsberry, A; Heerspink, HJL; McCullough, PA; Meyer, CJ; Packham, D; Pergola, PE; Rossing, P; Spinowitz, B; Sprague, SM; Warnock, DG | 1 |
| Agarwal, R; Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Chin, M; de Zeeuw, D; Krauth, M; Lambers Heerspink, HJ; McMurray, JJ; Meyer, CJ; Parving, HH; Pergola, PE; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Warnock, DG; Wittes, J | 1 |
| Fu, L; Gribble, GW | 1 |
| Appel, G | 1 |
| Bumeister, R; Chin, M; Chuang, JC; Lee, CY; Meyer, C; Sonis, ST; Ward, KW; Wigley, WC | 1 |
| Alguraan, Z; Banihani, S; Swedan, S | 1 |
| Hai, C; Li, W; Liao, N; Liu, R; Qin, X; Wang, X; Wang, Z; Zhang, W; Zhang, X | 1 |
| Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Christ-Schmidt, H; de Zeeuw, D; Goldsberry, A; Krauth, M; Lambers Heerspink, HJ; Linde, P; McMurray, JJ; Meyer, CJ; Parving, HH; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Wittes, J; Wrolstad, D | 1 |
| Himmelfarb, J; Tuttle, KR | 2 |
| Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Chin, M; Christ-Schmidt, H; de Zeeuw, D; Goldsberry, A; Houser, M; Krauth, M; Lambers Heerspink, HJ; McMurray, JJ; Meyer, CJ; Parving, HH; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Wittes, J; Wrolstad, D | 1 |
| Camer, D; Huang, XF; Szabo, A; Yu, Y | 1 |
| Chertow, GM; de Zeeuw, D | 1 |
| Chartoumpekis, DV; Sykiotis, GP | 1 |
| Kovács, T; Molnár, GA; Wittmann, I | 1 |
| Ellison, DH | 1 |
| Bakris, GL; Chin, MP; Linde, PG; McCullough, PA; Meyer, CJ; O'Grady, M; Packham, D; Reisman, SA; Vaziri, ND; Ward, KW; Warnock, DG | 1 |
| Van Biesen, W; Van Laecke, S; Vanholder, R | 1 |
| Jo, E; Li, S; Molero, JC; Tan, M; Wang, H; Xue, CC; Ye, JM; Zeng, XY; Zhou, X | 1 |
| de Zeeuw, D; Meyer, C | 1 |
| Bakris, GL; Chertow, GM; Chin, MP; de Zeeuw, D; Goldsberry, A; Linde, PG; McCullough, PA; McMurray, JJ; Meyer, CJ; Wittes, J; Wrolstad, D | 1 |
| Chin, MP; Meyer, CJ | 1 |
| Camer, D; Huang, XF | 1 |
| Cui, J; Jia, N; Li, Y; Wen, A; Wu, Y; Xi, M; Zhang, T | 1 |
| Abdelkader, D; Chen, Y; Hassan, W; Liu, J; Sun, H; Wang, X | 1 |
| Cai, YS; Gao, LX; Guo, YW; He, WF; Li, J; Li, YF; Liang, LF; Liu, HL | 1 |
| Guo, YW; He, WF; Li, J; Liu, HL; Xue, DQ; Yao, LG | 1 |
| Duarte, MF; Oliveira, PJ; Silva, FS | 1 |
| Gutiérrez, RMP | 1 |
| Fussenegger, M; Shao, J; Wang, Y; Xie, M; Xue, S; Yang, L; Ye, H; Yin, J; Yu, Y | 1 |
| Gbonjubola, VA; Islam, MS; Koorbanally, NA; Mohammed, A | 1 |
| Anand, S; Balakrishnan, A; Lakshmi, BS; Muthusamy, VS; Nithya, N; Sangeetha, KN; Sujatha, S; Velmurugan, D | 1 |
| Ferguson, DA; Huff, JW; Krauth, M; Meyer, CJ; Pergola, PE; Ruiz, S; Warnock, DG | 1 |
| Audhya, P; Christ-Schmidt, H; Grossman, EB; Huff, JW; Krauth, M; Meyer, CJ; Pergola, PE; Raskin, P; Ruiz, S; Toto, RD; Warnock, DG; Wittes, J | 1 |
| Kong, LY; Luo, JG; Nie, W; Sun, HB; Wang, XB; Yao, HQ; Yin, H | 1 |
| Cooper, ME; Thomas, MC | 1 |
| Van Laecke, S; Vanholder, R | 1 |
| Bittenbring, JT; Fliser, D; Rogacev, KS | 1 |
| Levey, AS; Sarnak, MJ; Upadhyay, A | 1 |
| Forman, JP; McMahon, GM | 1 |
| Abramowitz, MK; Bauer, C; Hostetter, TH; Melamed, ML; Turner, JM | 1 |
| Bargman, J; Burkart, J; Chertow, GM; Davies, S; Finkelstein, FO; Hebbar, S; Mehrotra, R; Ronco, C; Teitelbaum, I; Urakpo, K; Warnock, DG | 1 |
| Ali, S; McCullough, PA | 1 |
| Cantley, J; Hegarty, BD; Iseli, TJ; Kraegen, EW; Molero, JC; Wang, YP; Ye, JM; Ye, Y; Zeng, XY | 1 |
7 review(s) available for oleanolic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Topics: Acute Kidney Injury; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Glomerular Filtration Rate; Humans; Kelch-Like ECH-Associated Protein 1; Kidney Tubules; Mice; Molecular Targeted Therapy; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Proteasome Endopeptidase Complex; Proteolysis; Reactive Oxygen Species; Renal Insufficiency, Chronic; Signal Transduction; Ubiquitination | 2017 |
Pomegranate and type 2 diabetes.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Ellagic Acid; Flowers; Fruit; Humans; Hydrolyzable Tannins; Hypoglycemic Agents; Lipid Peroxidation; Lythraceae; Middle East; NF-kappa B; Oleanolic Acid; Plant Extracts; Polyphenols; PPAR gamma; Seeds; Triterpenes; Ursolic Acid | 2013 |
The molecular mechanisms underpinning the therapeutic properties of oleanolic acid, its isomer and derivatives for type 2 diabetes and associated complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Hypoglycemic Agents; Models, Biological; Oleanolic Acid; Oxidative Stress; Triterpenes; Ursolic Acid | 2014 |
Oleanolic, Ursolic, and Betulinic Acids as Food Supplements or Pharmaceutical Agents for Type 2 Diabetes: Promise or Illusion?
Topics: Anti-Inflammatory Agents; Betulinic Acid; Body Weight; Diabetes Mellitus, Type 2; Dietary Supplements; Hypoglycemic Agents; Illusions; Insulin Resistance; Molecular Structure; Oleanolic Acid; Pentacyclic Triterpenes; Triterpenes | 2016 |
Treatment of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diabetes Mellitus, Type 2; Disease Progression; Endothelin-1; Humans; Hypertension; Kidney Failure, Chronic; Oleanolic Acid; Pyridones; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Inflammation; Kidney Failure, Chronic; Oleanolic Acid; Peritoneal Dialysis; Prospective Studies; Research Design; Sample Size | 2012 |
Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl.
Topics: Animals; Antioxidants; Chronic Disease; Diabetes Mellitus, Type 2; Humans; Kidney Diseases; Kidney Function Tests; NF-E2-Related Factor 2; Oleanolic Acid; Oxidants | 2012 |
13 trial(s) available for oleanolic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation, Enzymologic; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Chronic; Liver; Male; Middle Aged; NF-E2-Related Factor 2; Oleanolic Acid | 2021 |
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
Topics: Aged; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Oleanolic Acid; Renal Dialysis; Treatment Outcome | 2018 |
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Oleanolic Acid; Renal Insufficiency, Chronic; Waist Circumference | 2018 |
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Glomerular Filtration Rate; Humans; Magnesium; Male; Middle Aged; Oleanolic Acid; Renal Insufficiency, Chronic | 2019 |
Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Oleanolic Acid; Olive Oil; Prediabetic State | 2019 |
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Topics: Adult; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Early Termination of Clinical Trials; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oleanolic Acid; Treatment Outcome | 2019 |
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
Topics: Anti-Inflammatory Agents; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Early Termination of Clinical Trials; Glomerular Filtration Rate; Humans; Oleanolic Acid; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Oleanolic Acid; Prognosis; Renal Insufficiency, Chronic; Young Adult | 2013 |
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; NF-E2-Related Factor 2; Oleanolic Acid; Renal Insufficiency, Chronic; Treatment Failure; Weight Loss | 2013 |
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Topics: Animals; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Heart Failure; Humans; Macaca fascicularis; Male; Oleanolic Acid; Rats; Renal Insufficiency, Chronic; Sodium; Urine; Water-Electrolyte Imbalance | 2014 |
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Topics: Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Oleanolic Acid; Patient Safety; Predictive Value of Tests; Reference Values; Renal Insufficiency, Chronic; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome | 2014 |
Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD.
Topics: Adult; Aged; Antioxidants; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Inflammation; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Oleanolic Acid; Oxidative Stress; Placebos; Time Factors | 2011 |
Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oleanolic Acid; Renal Insufficiency, Chronic; Spasm | 2011 |
41 other study(ies) available for oleanolic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Palbinone and triterpenes from Moutan Cortex (Paeonia suffruticosa, Paeoniaceae) stimulate glucose uptake and glycogen synthesis via activation of AMPK in insulin-resistant human HepG2 Cells.
Topics: AMP-Activated Protein Kinases; Cell Line, Tumor; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose; Glycogen; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hypoglycemic Agents; Insulin Resistance; Paeonia; Phosphorylation; Terpenes; Triterpenes | 2009 |
Absolute structures and bioactivities of euryspongins and eurydiene obtained from the marine sponge Euryspongia sp. collected at Iriomote Island.
Topics: Animals; Biological Products; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; Models, Molecular; Neoplasms; Porifera; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Sesquiterpenes | 2015 |
Effect of Nano-Oleanolic Acid Combined With Lipid-Lowering Ketones on Insulin Resistance in Rats with Gestational Diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Insulin Resistance; Ketones; Lipids; Oleanolic Acid; Pregnancy; Rats | 2022 |
Discovery of 12β-oxygenated oleanolic acid alkyl esters as potent and selective FXR modulators exhibiting hyperglycemia amelioration in vivo.
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Esters; Gluconeogenesis; Hyperglycemia; Hypoglycemic Agents; Liver; Mice; Mice, Inbred C57BL; Oleanolic Acid; Receptors, Cytoplasmic and Nuclear | 2022 |
Renoprotective effects of oleanolic acid and its possible mechanisms in rats with diabetic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Inflammation; Kidney; Lipids; Male; NF-kappa B; Oleanolic Acid; Rats; Rats, Sprague-Dawley; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2022 |
Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
Topics: Albumins; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Humans; Oleanolic Acid; Renal Insufficiency, Chronic; Retrospective Studies | 2019 |
Oleanolic acid induces a dual agonist action on PPARγ/α and GLUT4 translocation: A pentacyclic triterpene for dyslipidemia and type 2 diabetes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Diabetes Mellitus, Type 2; Dyslipidemias; Gene Expression Regulation; Glucose Transporter Type 4; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Mice; Myoblasts, Skeletal; Oleanolic Acid; PPAR alpha; PPAR gamma; Protein Transport; Signal Transduction | 2020 |
Taraxerol, a pentacyclic triterpenoid, from Abroma augusta leaf attenuates diabetic nephropathy in type 2 diabetic rats.
Topics: Animals; Computer Simulation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Hyperglycemia; Inflammation; Malvaceae; Molecular Docking Simulation; Oleanolic Acid; Plant Leaves; Rats; Rats, Wistar; Streptozocin; Up-Regulation | 2017 |
Discrimination of different geographic varieties of Gymnema sylvestre, an anti-sweet plant used for the treatment of type 2 diabetes.
Topics: 4-Chloro-7-nitrobenzofurazan; Deoxyglucose; Diabetes Mellitus, Type 2; Gymnema sylvestre; Hypoglycemic Agents; India; Oleanolic Acid; Plant Extracts; Plant Leaves; Saponins; Vietnam | 2018 |
The Effects of Plant-Derived Oleanolic Acid on Selected Parameters of Glucose Homeostasis in a Diet-Induced Pre-Diabetic Rat Model.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glucose; Homeostasis; Hypoglycemic Agents; Male; Oleanolic Acid; Prediabetic State; Rats; Rats, Sprague-Dawley | 2018 |
α-Glucosidase enzyme inhibitory effects and ursolic and oleanolic acid contents of fourteen Anatolian Salvia species.
Topics: Acetonitriles; alpha-Glucosidases; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Oleanolic Acid; Plant Extracts; Salvia; Triterpenes; Ursolic Acid | 2018 |
Efficient and scalable synthesis of bardoxolone methyl (cddo-methyl ester).
Topics: Anti-Inflammatory Agents; Chromatography; Diabetes Mellitus, Type 2; Esters; Humans; Molecular Structure; Oleanolic Acid; Renal Insufficiency, Chronic | 2013 |
Detecting and controlling diabetic nephropathy: what do we know?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Oleanolic Acid; Renin-Angiotensin System | 2013 |
Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.
Topics: Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Eating; Glucose; Kidney; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oleanolic Acid; Rats; Rats, Zucker | 2013 |
Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gluconeogenesis; Hypolipidemic Agents; Injections, Intraperitoneal; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Mitochondrial Turnover; Oleanolic Acid; Organ Size; Reactive Oxygen Species | 2013 |
New therapies for diabetic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2013 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
The paradox of bardoxolone methyl: a call for every witness on the stand?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Hepatic FoxO1 acetylation is involved in oleanolic acid-induced memory of glycemic control: novel findings from Study 2.
Topics: Acetylation; AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Forkhead Box Protein O1; Forkhead Transcription Factors; Histone Acetyltransferases; Liver; Male; Mice; Mice, Inbred C57BL; Oleanolic Acid; Phosphorylation; Sirtuin 1 | 2014 |
The paradox created by commenting on large clinical trial results.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Reply: To PMID 25307295.
Topics: Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Heart Failure; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Is B-type natriuretic peptide a risk factor for heart failure in patients treated with bardoxolone methyl?
Topics: Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Heart Failure; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects.
Topics: Animals; Aralia; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Oleanolic Acid; Oxidation-Reduction; Plant Bark; Plant Roots; Rats; Rats, Wistar; Saponins; Streptozocin; Triglycerides | 2015 |
Combination therapy with oleanolic acid and metformin as a synergistic treatment for diabetes.
Topics: Animals; Biomarkers; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucose; Homeostasis; Hypoglycemia; Hypoglycemic Agents; Insulin; Liver; Male; Metformin; Mice; Mice, Inbred C57BL; Oleanolic Acid; Organ Size; Phosphorylation; RNA | 2015 |
Brominated polyunsaturated lipids with protein tyrosine phosphatase-1B inhibitory activity from Chinese marine sponge Xestospongia testudinaria.
Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Hydrocarbons, Brominated; Marine Biology; Molecular Structure; Netherlands; Oleanolic Acid; Porifera; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Xestospongia | 2015 |
A new bioactive steroidal ketone from the South China Sea sponge Xestospongia testudinaria.
Topics: Animals; Cholestanols; Diabetes Mellitus, Type 2; Ketones; Molecular Structure; Oceans and Seas; Oleanolic Acid; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Steroids; Xestospongia | 2016 |
Hypolipidemic and hypoglycemic activities of a oleanolic acid derivative from Malva parviflora on streptozotocin-induced diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Hypoglycemic Agents; Hypolipidemic Agents; Male; Malva; Mice; Molecular Conformation; Oleanolic Acid; Streptozocin | 2017 |
A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.
Topics: Animals; Cell Engineering; Cell Line; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Gene Expression Regulation; Gene Regulatory Networks; Genetic Engineering; Glucagon-Like Peptide 1; Humans; Insulin Resistance; Liver Diseases; Male; Mice; Mice, Transgenic; Oleanolic Acid; Synthetic Biology | 2017 |
Inhibition of key enzymes linked to type 2 diabetes by compounds isolated from Aframomum melegueta fruit.
Topics: Acarbose; alpha-Amylases; Biological Assay; Catechols; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Alcohols; Fruit; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Kinetics; Oleanolic Acid; Pancreas; Phytotherapy; Plant Extracts; Plants, Medicinal; Solvents; Zingiberaceae | 2017 |
3beta-taraxerol of Mangifera indica, a PI3K dependent dual activator of glucose transport and glycogen synthesis in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Blood Glucose; Cell Survival; Deoxyglucose; Diabetes Mellitus, Type 2; Enzyme Activation; Glucose; Glycogen; Humans; Insulin Resistance; Mangifera; Mice; Oleanolic Acid; Phosphatidylinositol 3-Kinases; Plant Extracts | 2010 |
Synthesis of new α-glucosidase inhibitors based on oleanolic acid incorporating cinnamic amides.
Topics: alpha-Glucosidases; Amides; Cinnamates; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Ligands; Oleanolic Acid; Structure-Activity Relationship | 2011 |
Diabetes: bardoxolone improves kidney function in type 2 diabetes.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Inactivation, Metabolic; Kidney Failure, Chronic; NF-E2-Related Factor 2; Oleanolic Acid | 2011 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
Oleanolic acid reduces hyperglycemia beyond treatment period with Akt/FoxO1-induced suppression of hepatic gluconeogenesis in type-2 diabetic mice.
Topics: Animals; Base Sequence; Blood Glucose; Diabetes Mellitus, Type 2; DNA Primers; Forkhead Box Protein O1; Forkhead Transcription Factors; Gluconeogenesis; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Secretion; Liver; Male; Mice; Mice, Inbred C57BL; Oleanolic Acid; Proto-Oncogene Proteins c-akt; Triglycerides | 2012 |